The agreement is part of Zydus’s exclusive arrangement with Guardant Health to introduce the Shield test in the Indian market ...

Bernstein lifted its Guardant Health price target to $200 after UnitedHealth's Shield coverage decision. Here's what it means ...

One analyst called the insurer’s decision a “watershed moment” for liquid biopsy-based cancer screening and for the category ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening (CRC) is now covered for eligible UnitedHealth Group ...

Colorectal cancer is the second-leading cause of cancer-related death in the U.S., even though it is highly treatable if caught early.2 The American Cancer Society estimates that more than 150,000 ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and ...

(RTTNews) - Guardant Health, Inc. (GH) Tuesday announced that the Centers for Medicare & Medicaid Services or CMS has granted Advanced Diagnostic Laboratory Test or ADLT status to its Shield blood ...

Zydus Lifesciences and Apollo Hospitals partner to expand access to Shield Multi-Cancer Detection blood test in India, ...

Zydus Lifesciences has partnered with Apollo Hospitals to introduce the Shield multi-cancer detection test in India, made ...